-
1.发明申请SYSTEMS AND METHODS FOR APPLYING A SELECTED TREATMENT AGENT INTO CONTACT WITH TISSUE 审中-公开将选择的治疗剂与组织接触的系统和方法公开(公告)号：US20120209144A1
公开(公告)日：2012-08-16
申请号：US13454842
申请日：2012-04-24
Applicant: DAVID S. UTLEY , John W. Gaiser , Rachel Croft
Inventor： DAVID S. UTLEY , John W. Gaiser , Rachel Croft
CPC classification number: A61B18/1492 , A61B18/1477 , A61B2018/00214 , A61B2018/00232 , A61B2018/00553 , A61B2018/00797 , A61B2018/00815 , A61B2018/1425 , A61M25/0084
Abstract: Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.
Abstract translation: 通过将一种或多种治疗剂施用于存在异常神经症状或异常组织病状的区域处或附近的组织来治疗胃肠道疾病的系统和方法。 选择治疗剂以破坏异常神经通路和/或减轻异常组织状况。 治疗剂可以包括至少一种细胞因子和/或至少一种香草酸化合物以引起所需的组织应答。 系统和方法可以用作主要治疗方式，或作为新辅助治疗方式。
-
2.发明申请Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction 审中-公开用于将选定的治疗剂与组织接触以治疗括约肌功能障碍的系统和方法公开(公告)号：US20110071468A1
公开(公告)日：2011-03-24
申请号：US12927517
申请日：2010-11-17
Applicant: David S. Utley , John W. Gaiser , Rachel Croft
Inventor： David S. Utley , John W. Gaiser , Rachel Croft
IPC: A61M31/00
CPC classification number: A61B18/1477 , A61B1/31 , A61B18/02 , A61B18/08 , A61B18/1492 , A61B18/1815 , A61B18/20 , A61B2018/00214 , A61B2018/00232 , A61B2018/00267 , A61B2018/00482 , A61B2018/00553 , A61B2018/00797 , A61B2018/00815 , A61B2018/0091 , A61B2018/00916 , A61B2018/1861 , A61B2090/3782 , A61B2218/007
Abstract: Systems and methods apply a selected treatment agent or agents into contact with tissue at or in the region of a dysfunctional sphincter (in the case of GERD, fecal incontinence, or other dysfunctional sphincter disorders) to affect improved sphincter barrier function and/or to disrupt abnormal nerve pathways. The treatment agent can include at least one cytokine and/or at least one tissue bulking agent and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or applied as a supplementary treatment before; during or after a primary intervention.
Abstract translation: 系统和方法将选定的治疗剂或药剂与功能异常括约肌区域（或GERD，大便失禁或其他功能失调的括约肌疾病）区域或组织接触，以影响改善的括约肌屏障功能和/或破坏 异常神经通路。 处理剂可以包括至少一种细胞因子和/或至少一种组织填充剂和/或至少一种香草酸化合物以引起所需的组织应答。 系统和方法可以用作主要治疗方式，或作为补充治疗应用; 在主要干预期间或之后。
-
3.发明申请Unified systems and methods for controlling use and operation of a family of different treatment devices 有权用于控制不同处理装置的家庭的使用和操作的统一的系统和方法公开(公告)号：US20070294108A1
公开(公告)日：2007-12-20
申请号：US11895205
申请日：2007-08-23
Applicant: Jay Qin , Robin Bek , John Gaiser , Rachel Croft , Peter Muller , David Utley
Inventor： Jay Qin , Robin Bek , John Gaiser , Rachel Croft , Peter Muller , David Utley
IPC: G06Q50/00
CPC classification number: A61B18/00 , A61B18/12 , A61B18/1206 , A61B18/1477 , A61B18/1492 , A61B2017/00017 , A61B2017/00199 , A61B2017/00482 , A61B2018/00011 , A61B2018/00214 , A61B2018/00261 , A61B2018/00267 , A61B2018/00273 , A61B2018/00285 , A61B2018/00291 , A61B2018/00494 , A61B2018/0066 , A61B2018/00898 , A61B2018/1475 , A61B2218/002 , G06F19/00 , G06Q50/22
Abstract: Unified systems and methods enable control of the use and operation of a family of different treatment devices, to treat dysfunction in different regions of the body.
Abstract translation: 统一的系统和方法能够控制一系列不同治疗装置的使用和操作，以治疗身体不同区域的功能障碍。
-
公开(公告)号：US20070118108A1
公开(公告)日：2007-05-24
申请号：US11650079
申请日：2007-01-05
Applicant: Rachel Croft
Inventor： Rachel Croft
IPC: A61B18/14
CPC classification number: A61B18/1485 , A61B18/1477 , A61B2018/005 , A61B2018/1425 , A61B2018/1475
Abstract: Systems and methods treat hemorrhoids by introducing a treatment device into the anal canal to extend above a hemorrhoidal plexus and adjacent a tissue region containing blood vessels that feed the hemorrhoidal plexus. The systems and methods operate the treatment device to affect tissue morphology in the tissue region to occlude or otherwise reduce blood flow through the vessels.
Abstract translation: 系统和方法通过将治疗装置引入肛管以在痔疮丛上方延伸并且邻近包含供血痔丛的血管的组织区域来治疗痔疮。 系统和方法操作处理装置以影响组织区域中的组织形态以封闭或以其它方式减少通过血管的血液流动。
-
公开(公告)号：US20140107483A1
公开(公告)日：2014-04-17
申请号：US14055077
申请日：2013-10-16
Applicant: David S. UTLEY , SCOTT WEST , JOHN GAISER , RACHEL CROFT
Inventor： David S. UTLEY , SCOTT WEST , JOHN GAISER , RACHEL CROFT
CPC classification number: A61B18/1485 , A61B1/00087 , A61B8/12 , A61B18/02 , A61B18/1477 , A61B18/149 , A61B18/18 , A61B2017/00106 , A61B2018/00011 , A61B2018/00023 , A61B2018/00029 , A61B2018/00267 , A61B2018/005 , A61B2018/00553 , A61B2018/00642 , A61B2018/00702 , A61B2018/00791 , A61B2018/00982 , A61B2018/00994 , A61B2018/046 , A61B2018/1869 , A61B2018/2005
Abstract: A sphincter tissue region is treated using a support structure sized for advancement into the anal canal. At least one electrode is carried by the structure. A mechanism is coupled to the electrode to move the electrode between a first position retracted in the support structure and a second position extended from the support structure through surface tissue to penetrate a subsurface tissue region at or near a sphincter in the anal canal. A cable is coupled to the electrode to conduct energy for application by the electrode to form a lesion in the subsurface tissue region.
Abstract translation: 括约肌组织区域使用尺寸适合进入肛管的支撑结构来治疗。 该结构承载至少一个电极。 机构耦合到电极以在缩回到支撑结构中的第一位置和从支撑结构延伸穿过表面组织的第二位置之间移动电极，以穿透肛管内的括约肌处或附近的下表面组织区域。 电缆耦合到电极以传导电极施加的能量，以在地下组织区域中形成病变。
-
Patent Agency Ranking
公开(公告)号：US08597290B2
公开(公告)日：2013-12-03
申请号：US12799169
申请日：2010-04-20
Applicant: David Utley , Scott West , John Gaiser , Rachel Croft
Inventor： David Utley , Scott West , John Gaiser , Rachel Croft
IPC: A61B18/18
CPC classification number: A61B18/1485 , A61B1/00087 , A61B8/12 , A61B18/02 , A61B18/1477 , A61B18/149 , A61B18/18 , A61B2017/00106 , A61B2018/00011 , A61B2018/00023 , A61B2018/00029 , A61B2018/00267 , A61B2018/005 , A61B2018/00553 , A61B2018/00642 , A61B2018/00702 , A61B2018/00791 , A61B2018/00982 , A61B2018/00994 , A61B2018/046 , A61B2018/1869 , A61B2018/2005
Abstract: A sphincter tissue region is treated using a support structure sized for advancement into the anal canal. At least one electrode is carried by the structure. A mechanism is coupled to the electrode to move the electrode between a first position retracted in the support structure and a second position extended from the support structure through surface tissue to penetrate a subsurface tissue region at or near a sphincter in the anal canal. A cable is coupled to the electrode to conduct energy for application by the electrode to form a lesion in the subsurface tissue region.
-
7.发明授权Systems and methods for applying a selected treatment agent into contact with tissue 有权将选定的处理剂施用于与组织接触的系统和方法公开(公告)号：US08161976B2
公开(公告)日：2012-04-24
申请号：US11906457
申请日：2007-10-02
Applicant: David S Utley , John W Gaiser , Rachel Croft
Inventor： David S Utley , John W Gaiser , Rachel Croft
IPC: A61B17/00
CPC classification number: A61B18/1492 , A61B18/1477 , A61B2018/00214 , A61B2018/00232 , A61B2018/00553 , A61B2018/00797 , A61B2018/00815 , A61B2018/1425 , A61M25/0084
Abstract: Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.
Abstract translation: 通过将一种或多种治疗剂施用于存在异常神经症状或异常组织病状的区域处或附近的组织来治疗胃肠道疾病的系统和方法。 选择治疗剂以破坏异常神经通路和/或减轻异常组织状况。 治疗剂可以包括至少一种细胞因子和/或至少一种香草酸化合物以引起所需的组织应答。 系统和方法可以用作主要治疗方式，或作为新辅助治疗方式。
-
公开(公告)号：US07699844B2
公开(公告)日：2010-04-20
申请号：US11446771
申请日：2006-06-05
Applicant: David Utley , Scott West , John Gaiser , Rachel Croft
Inventor： David Utley , Scott West , John Gaiser , Rachel Croft
IPC: A61B18/18
CPC classification number: A61B18/1477 , A61B1/31 , A61B18/1485 , A61B2018/00267 , A61B2018/00482 , A61B2018/00553 , A61B2018/00797 , A61B2018/0091 , A61B2018/00916 , A61B2018/046 , A61B2090/3782 , A61B2218/007
Abstract: A sphincter tissue region is treated using a support structure sized for advancement into the anal canal. At least one electrode is carried by the structure. A mechanism is coupled to the electrode to move the electrode between a first position retracted in the support structure and a second position extended from the support structure through surface tissue to penetrate a subsurface tissue region at or near a sphincter in the anal canal. A cable is coupled to the electrode to conduct energy for application by the electrode to form a lesion in the subsurface tissue region.
Abstract translation: 括约肌组织区域使用尺寸适合进入肛管的支撑结构来治疗。 该结构承载至少一个电极。 机构耦合到电极以在缩回到支撑结构中的第一位置和从支撑结构延伸穿过表面组织的第二位置之间移动电极，以穿透肛管内的括约肌处或附近的下表面组织区域。 电缆耦合到电极以传导电极施加的能量，以在地下组织区域中形成病变。
-
9.发明授权Systems methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction 有权将选择的治疗剂施用于与组织接触以治疗括约肌功能障碍的系统方法公开(公告)号：US07458378B2
公开(公告)日：2008-12-02
申请号：US10912329
申请日：2004-08-05
Applicant: David S Utley , John W Gaiser , Rachel Croft
Inventor： David S Utley , John W Gaiser , Rachel Croft
CPC classification number: A61B18/1477 , A61B1/31 , A61B18/12 , A61B18/1206 , A61B18/1485 , A61B18/1492 , A61B2018/00011 , A61B2018/00029 , A61B2018/00077 , A61B2018/00148 , A61B2018/00214 , A61B2018/00232 , A61B2018/00261 , A61B2018/00267 , A61B2018/00273 , A61B2018/00285 , A61B2018/00291 , A61B2018/00482 , A61B2018/00553 , A61B2018/00654 , A61B2018/0066 , A61B2018/00702 , A61B2018/00755 , A61B2018/00791 , A61B2018/00797 , A61B2018/00815 , A61B2018/00875 , A61B2018/00898 , A61B2018/0091 , A61B2018/00916 , A61B2018/046 , A61B2018/1425 , A61B2018/1475 , A61B2090/3782 , A61B2218/002 , A61B2218/007
Abstract: Systems and methods apply a selected treatment agent or agents into contact with tissue at or in the region of a dysfunctional sphincter (in the case of GERD, fecal incontinence, or other dysfunctional sphincter disorders) to affect improved sphincter barrier function and/or to disrupt abnormal nerve pathways. The treatment agent can include at least one cytokine and/or at least one tissue bulking agent and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or applied as a supplementary treatment before, during or after a primary intervention.
Abstract translation: 系统和方法将选定的治疗剂或药剂与功能异常括约肌区域（或GERD，大便失禁或其他功能失调的括约肌疾病）区域或组织接触，以影响改善的括约肌屏障功能和/或破坏 异常神经通路。 处理剂可以包括至少一种细胞因子和/或至少一种组织填充剂和/或至少一种香草酸化合物以引起所需的组织应答。 这些系统和方法可以用作主要治疗方式，或在主要干预之前，期间或之后作为补充治疗应用。
-
10.发明申请Systems and methods for applying a selected treatment agent into contact with tissue 有权将选定的处理剂施用于与组织接触的系统和方法公开(公告)号：US20080033374A1
公开(公告)日：2008-02-07
申请号：US11906457
申请日：2007-10-02
Applicant: David Utley , John Gaiser , Rachel Croft
Inventor： David Utley , John Gaiser , Rachel Croft
CPC classification number: A61B18/1492 , A61B18/1477 , A61B2018/00214 , A61B2018/00232 , A61B2018/00553 , A61B2018/00797 , A61B2018/00815 , A61B2018/1425 , A61M25/0084
Abstract: Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.
Abstract translation: 通过将一种或多种治疗剂施用于存在异常神经症状或异常组织病状的区域处或附近的组织来治疗胃肠道疾病的系统和方法。 选择治疗剂以破坏异常神经通路和/或减轻异常组织状况。 治疗剂可以包括至少一种细胞因子和/或至少一种香草酸化合物以引起所需的组织应答。 系统和方法可以用作主要治疗方式，或作为新辅助治疗方式。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.017 seconds)
